BATE
发表于 2025-3-30 12:08:23
https://doi.org/10.1007/978-94-009-6192-0(2–4). In 1971 Weller published a seminal two part article with the apt title, “The cytomegaloviruses: ubiquitous agents with protean clinical manifestations” (5,6). CMV has continued to reveal itself in many clinical settings from the brain of newborns to the retina of AIDS patients.
Confess
发表于 2025-3-30 13:37:00
http://reply.papertrans.cn/15/1467/146654/146654_52.png
俗艳
发表于 2025-3-30 20:19:06
http://reply.papertrans.cn/15/1467/146654/146654_53.png
surmount
发表于 2025-3-30 22:05:09
http://reply.papertrans.cn/15/1467/146654/146654_54.png
SENT
发表于 2025-3-31 02:20:23
http://reply.papertrans.cn/15/1467/146654/146654_55.png
我没有强迫
发表于 2025-3-31 07:02:45
https://doi.org/10.1007/978-3-642-84238-2lantation in a patient with acute lymphoblastic leukemia was published in 1989 by Kessinger et al. (5) showing clear evidence of trilineage engraftment. This was followed in 1994 and 1995, by various reports of successful allogeneic PBSC transplantations using PBSC from rhG-CSF mobilized donors (6–9).
Goblet-Cells
发表于 2025-3-31 12:27:49
P. K. Banerjee,G. F. Dargush,K. Honkala CBU. While there are availability and logistical differences between these alternative donors, a clear preference in choosing an alternative donor for transplantation awaits prospective randomized trials.
Ventilator
发表于 2025-3-31 13:37:29
Boundary Element Methods in Heat Transfertechniques of typing by molecular biology has decreased the probability of finding a fully matched donor for class I and class II HLA antigens (1-5). Despite a bone marrow donor registry which contains more than 4 million bone marrow donors worldwide, some patients cannot be transplanted because of the lack of an HLA identical donor.
cogent
发表于 2025-3-31 19:31:37
http://reply.papertrans.cn/15/1467/146654/146654_59.png
沟通
发表于 2025-3-31 23:20:34
Y. Abousleiman,A. H.-D. Cheng,J. C. Roegiersnterleukins), vaccines, and adoptive immunotherapy. This chapter will discuss aspects of the Epstein-Barr virus and the human immune response against EBV. The clinical role of adoptive immunotherapy in the treatment of EBV-induced malignancies will be presented, as well as the areas of current investigation.